DiaMedica Therapeutics Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-5.1M | $-5.2M | $-5.2M | $-4.5M | $-4.5M | $-5.3M | $-3.8M | $-3.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $10.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $7.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $443.0K | $488.0K | $456.0K | $425.0K | $380.0K | $422.0K | $411.0K | $418.0K |
| Net Cash from Operating Activities | $-4.5M | $-6.7M | $-3.8M | $-4.8M | $-5.0M | $-5.1M | $-2.8M | $-2.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $9.0K | $3.0K | $10.0K | $4.0K | $7.0K | $32.0K | $43.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $4.7M | $4.2M | $6.1M | $1.2M | $-28.1M | $2.5M | $4.7M | $2.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $11.8M | $-1.0K | $-1.0K | $-6.0K | $36.9M | $-1.0K | $-1.0K | $-2.0K |
| Net Change in Cash | $12.0M | $-2.4M | $2.3M | $-3.6M | $3.7M | $-2.6M | $2.0M | $-291.0K |
| Free Cash Flow | $-4.5M | $-6.7M | $-3.8M | $-4.8M | $-5.0M | $-5.1M | $-2.8M | $-2.4M |